

Financial news for TSRO dated on 2019-01-08: TD Ameritrade IMX Continued Its Dip In December, Falling To A More Than Two-Year Low

Financial news for TSRO dated on 2019-01-07: Investor Movement Index December Summary

Financial news for TSRO dated on 2019-01-07: Tesaro Option Alert: Jan 18 \$40 Calls at the Ask: 526 @ \$34.5 vs 4356 OI; Earnings 2/26 After Close [est] Ref=\$74.49

Financial news for TSRO dated on 2019-01-07: Tesaro Option Alert: Jan 18 \$40 Calls Sweep (2) near the Ask: 1000 @ \$34.55 vs 4356 OI; Earnings 2/26 After Close [est] Ref=\$74.485

Financial news for TSRO dated on 2018-12-26: Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James

Financial news for TSRO dated on 2018-12-11: Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Financial news for TSRO dated on 2018-12-10: Benzinga's Top Upgrades, Downgrades For December 10, 2018

Financial news for TSRO dated on 2018-12-10: Barclays Downgrades Tesaro to Equal-Weight, Raises Price Target to \$75

Financial news for TSRO dated on 2018-12-04: Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal

Financial news for TSRO dated on 2018-12-04: 10 Biggest Price Target Changes For Tuesday

Financial news for TSRO dated on 2018-12-04: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Tues., Dec. 4, 2018

Financial news for TSRO dated on 2018-12-04: Benzinga's Top Upgrades, Downgrades For December 4, 2018

Financial news for TSRO dated on 2018-12-04: Wedbush Downgrades Tesaro to Neutral, Raises Price Target to \$75

Financial news for TSRO dated on 2018-12-04: Leerink Swann Downgrades Tesaro to Market Perform, Raises Price Target to \$75

Financial news for TSRO dated on 2018-12-04: Gabelli & Co. Downgrades Tesaro to Hold

Financial news for TSRO dated on 2018-12-04: Guggenheim Downgrades Tesaro to Neutral, Raises Price Target to \$75

Financial news for TSRO dated on 2018-12-04: SunTrust Robinson Humphrey Downgrades Tesaro to Hold, Raises Price Target to \$75

Financial news for TSRO dated on 2018-12-04: 56 Biggest Movers From Yesterday

Financial news for TSRO dated on 2018-12-03: Mid-Afternoon Market Update: Tesaro Climbs On Acquisition News; Tonix Pharmaceuticals Shares Slide

Financial news for TSRO dated on 2018-12-03: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for TSRO dated on 2018-12-03: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Mon., Dec. 3, 2018

Financial news for TSRO dated on 2018-12-03: Mid-Day Market Update: Hexindai Falls After Q2 Results; Global Blood Therapeutics Shares Surge

Financial news for TSRO dated on 2018-12-03: Mid-Morning Market Update: Markets Open Higher; Nexstar to buy Tribune Media for \$46.50/Share

Financial news for TSRO dated on 2018-12-03: GlaxoSmithKline Strikes \$5B M&A Deal With Tesaro In Quest To Boost Oncology Franchise

Financial news for TSRO dated on 2018-12-03: Tesaro shares are trading higher after receiving a \$75/share cash offer from GlaxoSmithKline.

Financial news for TSRO dated on 2018-12-03: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for TSRO dated on 2018-12-03: Clovis Oncology Shares Up 32% Premarket, Likely Trading Higher In Sympathy With 60% Upside Move In Tesaro Following \$6B Deal For Glaxo To Buy Tesaro

Financial news for TSRO dated on 2018-12-03: GlaxoSmithKline to Acquire TESARO for \$75/Share Cash, Deal Worth \$5.1B Including the Assumption of Debt

Financial news for TSRO dated on 2018-11-26: 21 Stocks Moving In Monday's Pre-Market Session

Financial news for TSRO dated on 2018-11-21: 50 Biggest Movers From Yesterday

Financial news for TSRO dated on 2018-11-19: '\$TSRO cancelled out of next week's ISI healthcare conference, so.... ???' -Tweet From STAT News' Adam Feuerstein

Financial news for TSRO dated on 2018-11-19: TESARO Shares Spike 14% Over Last 20 Mins., Very Heavy Volume Came Into Stock Over Last 4 Mins As \$36 Level Was Breached; Traders Attributing Move To Chatter Co. Cancelled Out Of An Upcoming Conference

Financial news for TSRO dated on 2018-11-19: 55 Biggest Movers From Friday

Financial news for TSRO dated on 2018-11-16: Tesaro Shares Resume Trade, Up 29.9%

Financial news for TSRO dated on 2018-11-16: TESARO Shares Halted On Circuit Breaker To The Downside; Stock Down 8.7% From Session High, Still Up 31.9% For Session

Financial news for TSRO dated on 2018-11-16: TESARO Shares Resume Trade, Continue Higher, Now Up 37.8%

Financial news for TSRO dated on 2018-11-16: TESARO Shares Halted On Circuit Breaker, Up 37.3%

Financial news for TSRO dated on 2018-11-16: Tesaro shares gain 29.5% amid speculation the company is exploring a sale.

Financial news for TSRO dated on 2018-11-16: TESARO Shares Resume Trade, Now Up 28% For Session

Financial news for TSRO dated on 2018-11-16: Tesaro Shares Halted On Circuit Breaker; Bloomberg Reports The Company Is Exploring A Sale

Financial news for TSRO dated on 2018-11-12: Jefferies Maintains Hold on Tesaro, Lowers Price Target to \$25

Financial news for TSRO dated on 2018-11-12: 85 Biggest Movers From Friday

Financial news for TSRO dated on 2018-11-09: TESARO Shares Resume Trade, Down 9.8%

Financial news for TSRO dated on 2018-11-09: UPDATE: TESARO Says Will Highlight Data Presented At Society for Immunotherapy of Cancer Will Be Featured On Co. Webcast Nov. 12

Financial news for TSRO dated on 2018-11-09: TESARO Issues Release Highlighting 'Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combo with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment'

Financial news for TSRO dated on 2018-11-09: Tesaro Shares Halted On Circuit Breaker, Down 9.8%

Financial news for TSRO dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for TSRO dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for TSRO dated on 2018-11-02: The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

Financial news for TSRO dated on 2018-11-01: UPDATE: Tesaro Raises FY18 Sales Outlook From \$250M-\$265M to \$258M-\$265M vs \$258.4M Est.

Financial news for TSRO dated on 2018-11-01: Tesaro Raises FY18 Guidance

Financial news for TSRO dated on 2018-11-01: TESARO, Inc. Q3 EPS \$(2.49) Beats \$(2.55) Estimate, Sales \$63.6M Miss \$71.76M Estimate

Financial news for TSRO dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for TSRO dated on 2018-10-29: TESARO Announces Achievement Of ZEJULA Prostate Cancer Development Milestones By Janssen; Receives \$18M Milestone Payment

From Janssen

Financial news for TSRO dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for TSRO dated on 2018-10-24: Shares of Tesaro are trading down 14.1%; Over the weekend, competitors AstraZeneca and Merck & Co. presented phase 1 results for their ovarian cancer drug Lynparza, a rival to Tesaro's Zejula.

Financial news for TSRO dated on 2018-10-22: 11 Stocks That Moved From ESMO 2018

Financial news for TSRO dated on 2018-10-20: TESARO Announces Data Presented Indicate That Tsr-042 Is Well Tolerated and Has Robust Activity in Patients With Msi-h Endometrial Cancer at ESMO 2018

Financial news for TSRO dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for TSRO dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On Tesaro with Overweight Rating, Announces \$57 Price Target

Financial news for TSRO dated on 2018-09-25: Leerink Swann Initiates Coverage On Tesaro with Outperform Rating, Announces \$48 Price Target

Financial news for TSRO dated on 2018-09-06: 54 Biggest Movers From Yesterday

Financial news for TSRO dated on 2018-09-05: RBC Out Negative On TESARO, Says High Rate Of Unconfirmed Responses Creates Concern That PD-1 + Zejula May Not Differentiate From Keytruda Monotherapy Or Keytruda & Chemo Combos

Financial news for TSRO dated on 2018-09-05: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TSRO dated on 2018-09-05: TESARO 8-K Shows Co. To Reaffirm 2H'18 Guidance

Financial news for TSRO dated on 2018-09-05: UPDATE: TESARO Notes 9 Of 14 Patients In JASPER Trial 'had objective responses by RECIST criteria at the time of the analysis'

Financial news for TSRO dated on 2018-09-05: TESARO 8-K Highlights Initiation Of Second Stage Of Its JASPER Trial Of ZEJULA In Combo With TSR-042 In Non-Small Cell Lung Cancer; Reports All Evaluable Patients Experienced Tumor Shrinkage

Financial news for TSRO dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for TSRO dated on 2018-09-05: 26 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TSRO dated on 2018-09-04: Tesaro Announces Initiation of 2nd Stage of JASPER Study of ZEJULA in Combo With TSR-042

Financial news for TSRO dated on 2018-08-07: Stocks Which Set New 52-Week Low Yesterday, August 6th

Financial news for TSRO dated on 2018-08-06: Stocks Which Set New 52-Week Lows Friday, August 3rd

Financial news for TSRO dated on 2018-08-06: Barclays Maintains Overweight on Tesaro, Lowers Price Target to \$56

Financial news for TSRO dated on 2018-08-06: Bank of America Downgrades Tesaro to Neutral

Financial news for TSRO dated on 2018-08-06: 66 Biggest Movers From Friday

Financial news for TSRO dated on 2018-08-03: 56 Stocks Moving In Friday's Mid-Day Session

Financial news for TSRO dated on 2018-08-03: Stocks Which Set New 52-Week Low Yesterday, August 2nd

Financial news for TSRO dated on 2018-08-03: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for TSRO dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for TSRO dated on 2018-08-02: Tesaro shares are trading down 12.8% after the company missed Q2 earnings estimates and lowered 2018 sales guidance.

Financial news for TSRO dated on 2018-08-02: 8 Stocks Moving In Thursday's After-Hours Session

Financial news for TSRO dated on 2018-08-02: TESARO Lowers FY18 Sales From \$310-\$345M To \$250-\$265M

Financial news for TSRO dated on 2018-08-02: Tesaro Q2 EPS \$(3.04) Misses \$(2.65) Estimate, Sales \$57.208M Miss \$63.34M Estimate

Financial news for TSRO dated on 2018-08-02: Stocks Which Set New 52-Week Low Yesterday, August 1st

Financial news for TSRO dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for TSRO dated on 2018-08-01: Stocks Which Set New 52-Week Low Yesterday, July 31

Financial news for TSRO dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for TSRO dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for TSRO dated on 2018-07-27: Stocks Which Set New 52-Week Low Yesterday, July 26th:

Financial news for TSRO dated on 2018-07-26: Stocks Which Set New 52-Week Low Yesterday, July 25th

Financial news for TSRO dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for TSRO dated on 2018-07-25: Stocks Which Set New 52-Week Lows Yesterday, July 24th:

Financial news for TSRO dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for TSRO dated on 2018-06-29: TESARO Draws \$200 Million From 2nd Tranche of Term Loan Financing

Financial news for TSRO dated on 2018-06-28: TESARO Enters Asset Purchase Agreement with TerSera Therapeutics LLC for VARUBI in the U.S. and Canada, Tesaro To Receive \$40M Plus Additional Milestone Payments

Financial news for TSRO dated on 2018-06-21: 50 Biggest Movers From Yesterday

Financial news for TSRO dated on 2018-06-20: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TSRO dated on 2018-06-20: SunTrust Analyst Says Tesaro Could Be Worth \$153/Share In Takeover

Financial news for TSRO dated on 2018-06-20: Hearing Citi Out Positive On Tesaro, Says There DCF Model Suggests An M&A Valuation Of \$140-\$213/Share

Financial news for TSRO dated on 2018-06-20: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TSRO dated on 2018-06-19: Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

Financial news for TSRO dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for TSRO dated on 2018-06-13: Tesaro Shares Spike ~\$0.50 Higher Over Last Min. As Traders Circulate Questionable Chatter Deal Coming; Stock Now Up 3.3% For Session

Financial news for TSRO dated on 2018-06-05: TESARO Late Monday Summarized TOPACIO And QUADRA Trial Results Presented At 2018 ASCO Annual Meeting

Financial news for TSRO dated on 2018-06-05: TESARO Announces Collaboration With Genentech to Evaluate ZEJULA in Combination With Anti-PD-L1 Cancer Immunotherapy and

MEK Inhibitor in Platinum-Sensitive Ovarian Cancer

Financial news for TSRO dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for TSRO dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for TSRO dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for TSRO dated on 2018-05-31: 41 Biggest Movers From Yesterday

Financial news for TSRO dated on 2018-05-22: Tesaro Shares Up 7.5% On Circulating Speculation That Gilead Is In Advanced Talks To Acquire Co.

Financial news for TSRO dated on 2018-05-22: Tesaro Shares Spike ~\$0.70 Over Last Min. As Hearing Speculation Gilead Is In Advanced Talks To Buy Co.

Financial news for TSRO dated on 2018-05-04: Credit Suisse Maintains Outperform on Tesaro, Lowers Price Target to \$128.00

Financial news for TSRO dated on 2018-05-03: Tesaro Sees FY18 Sales \$310M-\$345M vs \$311.04M Est.

Financial news for TSRO dated on 2018-05-03: Tesaro Q1 EPS \$(2.98) Misses \$(2.67) Estimate, Sales \$48.869M Miss \$57.92M Estimate

Financial news for TSRO dated on 2018-05-02: 8 Biggest Price Target Changes For Wednesday

Financial news for TSRO dated on 2018-05-02: Argus Research Maintains Buy on Tesaro, Lowers Price Target to \$110

Financial news for TSRO dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for TSRO dated on 2018-04-24: TESARO Reports ZEJULA Met Primary Endpoint In Quadra Trial

Financial news for TSRO dated on 2018-04-13: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for TSRO dated on 2018-04-11: TESARO Enters Exclusive Distribution Deal With Medison To Commercialize ZEJULA In Israel

Financial news for TSRO dated on 2018-04-05: 8 Biotech Stocks With Clinical Trial Outcomes In April

Financial news for TSRO dated on 2018-03-27: Benzinga Pro's 5 Stocks To Watch Today

Financial news for TSRO dated on 2018-03-26: TESARO Shares Up 4.6% In After Hours Trading Following 'Compelling Clinical Activity' In TOPACIO Trial For Ovarian Cancer

Financial news for TSRO dated on 2018-03-26: UPDATE: TESARO Says Data From TOPACIO Trial Showed 'Potential approach to reduce incidence of Grade 3 or 4 thrombocytopenia identified based on retrospective analysis of data from Phase 3 NOVA trial'

Financial news for TSRO dated on 2018-03-26: TESARO Reports Data From TOPACIO Trial Showed 'Efficacy of niraparib in combination with an anti-PD-1 mAb surpasses historical efficacy benchmarks for PD-1 or PARP monotherapies'

Financial news for TSRO dated on 2018-03-26: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for TSRO dated on 2018-03-07: Form 4 Filings From Tesaro Late Tuesday Shows New Enterprise Associates Bought Total of 116.445K Shares At Avg. Prices Ranging From \$54.32 to \$59.82

Financial news for TSRO dated on 2018-03-05: Form 4 Filing Earlier Shows Tesaro CEO Moulder Bought 5K Shares at Avg. Prices Ranging From \$56.86 to \$57.14

Financial news for TSRO dated on 2018-03-01: 50 Biggest Movers From Yesterday

Financial news for TSRO dated on 2018-02-28: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TSRO dated on 2018-02-28: Barclays Maintains Equal-Weight on

Tesaro, Lowers Price Target to \$90.00

Financial news for TSRO dated on 2018-02-28: Credit Suisse Maintains Outperform on Tesaro, Lowers Price Target to \$141.00

Financial news for TSRO dated on 2018-02-28: 31 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TSRO dated on 2018-02-27: 12 Stocks Moving In Tuesday's After-Hours Session

Financial news for TSRO dated on 2018-02-27: TESARO Shares Down 9% After Hours As Co. Reported Q4 EPS \$(3.35) vs \$(2.39) Est., Sales \$48.0M vs \$55.21 Est.; Sees FY18 Sales \$310M-\$345M vs \$383.97M Est.

Financial news for TSRO dated on 2018-02-26: TESARO Announces Collaboration With Genentech to Evaluate Combination of ZEJULA and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer

Financial news for TSRO dated on 2018-02-22: Evercore ISI Group Upgrades Tesaro to Outperform

Financial news for TSRO dated on 2018-01-23: 33 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TSRO dated on 2018-01-23: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TSRO dated on 2018-01-23: AbbVie, Broadcom, Tesaro, HMMJ: 'Fast Money' Picks For January 23

Financial news for TSRO dated on 2018-01-16: TESARO Shares Down 8% Following Update To VARUBI US Prescribing Information Fri. Afternoon; Stock Has Fallen 5 Sessions In A Row, Down ~16% Since Jan. 9

Financial news for TSRO dated on 2018-01-16: Benzinga Pro's 5 Stocks To Watch Today

Financial news for TSRO dated on 2018-01-16: Tesaro Inc. Shares Down 5.16% Premarket Following Reports That Chemo Nausea Med Varubi's Warning Label Updated

Financial news for TSRO dated on 2018-01-12: Tesaro Full Statement On VARUBI

Financial news for TSRO dated on 2018-01-12: Tesaro Updates Prescribing Info For VARUBI, Changes Label Contraindications, Warning and Precautions, and Adverse Reactions, Anaphylaxis, Anaphylactic Shock and Other Reactions Have Been Reported

Financial news for TSRO dated on 2018-01-02: TESARO Shares Down 9% Tues.; Analysts At Both Cowen And Piper Jaffray Lowered Price Targets On Stock To \$80 Earlier

Financial news for TSRO dated on 2017-12-15: TESARO Reports Availability Of ZEJULA For Women With Recurrent Ovarian Cancer In Germany

Financial news for TSRO dated on 2017-11-28: TESARO Reports Availability Of VARUBI IV For Delayed Nausea, Vomiting Associated With Cancer Chemotherapy

Financial news for TSRO dated on 2017-11-21: TESARO Secures \$500M Non-Dilutive Term Loan Financing

Financial news for TSRO dated on 2017-11-20: TESARO Announces European Commission Approval of ZEJULA for Women With Recurrent Ovarian Cancer

Financial news for TSRO dated on 2017-11-15: Benzinga's Top Upgrades, Downgrades For November 15, 2017

Financial news for TSRO dated on 2017-11-15: Leerink Swann Upgrades Tesaro to Outperform

Financial news for TSRO dated on 2017-11-09: Adam Feuerstein Tweets: \$TSRO comments (negatively) on \$AZN Lynparza Q3 sales. Interesting. Don't see this often, so publicly. Per Leerink note.

Financial news for TSRO dated on 2017-11-09: 57 Biggest Movers From Yesterday

Financial news for TSRO dated on 2017-11-08: Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market

Financial news for TSRO dated on 2017-11-08: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TSRO dated on 2017-11-08: Morgan Stanley Maintains Overweight on Tesaro, Lowers Price Target to \$165.00

Financial news for TSRO dated on 2017-11-08: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TSRO dated on 2017-11-07: Tesaro Reports Q3 EPS \$(0.47) vs \$(0.93) Est., Sales \$142.8M vs \$132.78M Est.

Financial news for TSRO dated on 2017-10-26: OPKO Health Licensee TESARO Announces FDA Approval of VARUBI IV

Financial news for TSRO dated on 2017-10-26: Tesaro Shares Move Higher On Latest FDA Approval; Analyst Is 'Highly Encouraged'

Financial news for TSRO dated on 2017-10-26: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for TSRO dated on 2017-10-25: Teasro Announces FDA Approves VARUBI IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy

Financial news for TSRO dated on 2017-10-25: REMINDER: Tesaro Has PDUFA Date For Rolapitant-Intravenous Today

Financial news for TSRO dated on 2017-10-23: Benzinga's Top Upgrades, Downgrades For October 23, 2017

Financial news for TSRO dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for TSRO dated on 2017-10-23: Barclays Initiates Coverage On Tesaro with Equal-Weight Rating, Announces \$135.00 Price Target

Financial news for TSRO dated on 2017-10-12: 4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate

Financial news for TSRO dated on 2017-10-12: Benzinga's Top Upgrades, Downgrades For October 12, 2017

Financial news for TSRO dated on 2017-10-12: H.C. Wainwright Initiates Coverage On Tesaro with Buy Rating, Announces \$158.00 Price Target

Financial news for TSRO dated on 2017-09-28: Attention Biotech Investors, Here's Your PDUFA Primer For October

Financial news for TSRO dated on 2017-09-15: Tesoro's Niraparib for the Treatment of Recurrent Ovarian Cancer Recommended by the EU Medicines Agency for Approval

Financial news for TSRO dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for TSRO dated on 2017-09-08: Tesaro Sheds \$20 Over The Last Three Days

Financial news for TSRO dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Tesaro with In-Line Rating, Announces \$121.00 Price Target

Financial news for TSRO dated on 2017-08-14: 13F From Omega Shows Exited Position In Tesaro, Williams Partners, Parsley Energy, Pandora

Financial news for TSRO dated on 2017-08-08: TESARO Reports Q2 EPS \$(2.82) vs \$(2.49) Est., Sales \$28.8M vs \$17.6M Est.

Financial news for TSRO dated on 2017-08-08: A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision

Financial news for TSRO dated on 2017-07-14: Wall Street's M&A Chatter From July 13: Tesaro, Time, Frontier Communications, First Citizens BancShares, Brink's-Maco Transportadora

Financial news for TSRO dated on 2017-07-13: Mid-Afternoon Market Update: Crude Oil Up 1%; DragonWave Shares Plunge

Financial news for TSRO dated on 2017-07-13: TESARO Spokesperson Declines Comment Following Report From CNBC's David Faber Suggesting Co.'s Sale Process Is Unlikely To Result In A Deal

Financial news for TSRO dated on 2017-07-13: 10 Biggest Mid-Day Losers For Thursday

Financial news for TSRO dated on 2017-07-13: Mid-Day Market Update: Yandex Jumps Following Announcement Of Deal With Uber; Amicus Therapeutics Shares Drop

Financial news for TSRO dated on 2017-07-13: Tesaro Sale Process Unlikely To Result In Deal According To CNBC's David Faber

Financial news for TSRO dated on 2017-06-21: Wall Street's M&A Chatter From June 20: Calpine, Parexel, Gilead, Spherix-Hoth Therapeutics, Norsat-Hytera

Financial news for TSRO dated on 2017-06-19: 10 Biggest Mid-Day Losers For Monday

Financial news for TSRO dated on 2017-06-19: Tesaro Comes Roaring Back From Much Lower Open

Financial news for TSRO dated on 2017-06-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for TSRO dated on 2017-06-15: Goldman Sachs Global Healthcare Conference Concludes Today, Presenters Include: Gilead, Tesaro, Ironwood Pharmaceuticals and Alkermes

Financial news for TSRO dated on 2017-06-14: Wall Street's M&A Chatter From June 13: Brookdale, Etsy, Roche-Tesaro

Financial news for TSRO dated on 2017-06-13: Tesaro Is A Top Rumor Mill Stock Right Now; Here Is A Timeline Of The Chatter

Financial news for TSRO dated on 2017-06-13: German Media Co. Handelszeitung Began Earlier Rumor Of Roche Interest In Tesaro, Not FT's Dealreporter

Financial news for TSRO dated on 2017-06-13: Adam Feuerstein Tweets: Hmmm. Buying \$TSRO at that valuation would be very unlike Roche.

Financial news for TSRO dated on 2017-06-13: Wall Street's M&A Chatter From June 12: Neuroderm, Penn Virginia, Tesaro, Synaptics-Conexant

Financial news for TSRO dated on 2017-06-12: TESARO Shares Jump ~\$6 Over Last Min As Traders Circulating Takeover Chatter

Financial news for TSRO dated on 2017-06-12: Tesaro Spikes Higher on Volume

Financial news for TSRO dated on 2017-06-12: UPDATE: Tesaro Says Janssen Anticipates Re-opening Enrollment for Galahad Trial Soon -8-K

Financial news for TSRO dated on 2017-06-12: Tesaro Says on June Janssen Updated Clinicaltrials.gov Website to Reflect Janssen had Placed Temporary Enrollment Hold in Galahad Trial; Says Galahad Trial Not on Clinical Hold, Temporary Enrollment Hold Not Due to Safety Concerns

Financial news for TSRO dated on 2017-06-12: Janssen and TESARO GALAHAD Trial Puts Patient Enrollment on Temporary Hold

Financial news for TSRO dated on 2017-06-09: Johnson & Johnson, Tesaro Niraparib Trial Enrollment Suspension Not Related To Safety

Financial news for TSRO dated on 2017-06-09: Tesaro Volatile After Johnson & Johnson Suspends Enrollment In Prostate Cancer Trial

Financial news for TSRO dated on 2017-06-09: JNJ Spokesperson Says, 'Our team put a temporarily hold on enrollment so we could assess the enrolled currently patients against the protocol criteria. We need to make sure we don't over-enroll some patient types and under-enroll others.'

Financial news for TSRO dated on 2017-06-09: Johnson & Johnson Spokesperson Tells Benzinga TESARO's Niraparib Study Enrollment Is, 'on temporary hold and we anticipate re-opening enrollment soon. The hold is not related to safety.'

Financial news for TSRO dated on 2017-06-09: TESARO Shares Bounce ~\$13 Off Session Lows As Wells Fargo Defends

Financial news for TSRO dated on 2017-06-09: Johnson & Johnson Suspends Enrollment of TESARO's Niraparib Phase 2 Prostate Cancer Trial Pending Review Of Data Collected

Financial news for TSRO dated on 2017-06-05: Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data

Financial news for TSRO dated on 2017-06-01: Fast Money Picks For June 1

Financial news for TSRO dated on 2017-06-01: Wall Street's M&A Chatter from May 31:

Tesaro, Gener8 Maritime, Pinnacle Foods

Financial news for TSRO dated on 2017-05-31: Adam Feuerstein Tweets '\$TSRO "for sale" news good reminder: Plenty 'o PARP data coming. \$AZN Olympiad breast at #ASCO17 (plenary) \$CLVS ARIEL-3 end of June'

Financial news for TSRO dated on 2017-05-31: Adam Feuerstein Tweets 'I would say \$PFE \$MDVN deal is a cautionary tale that makes potential \$TSRO suitors hesitant.'

Financial news for TSRO dated on 2017-05-31: UPDATE: Tesaro Explores Sale, 'But interest from bidders has been lukewarm...and it is possible there will be no deal in the foreseeable future'

Financial news for TSRO dated on 2017-05-31: Tesaro, Clovis Shares Spike Higher Amid Report Tesaro is Exploring Sale, Has Asked for Initial Bids in Recent Weeks

Financial news for TSRO dated on 2017-05-25: Oppenheimer Initiates Coverage On Tesaro with Outperform Rating, Announces \$183.00 Price Target

Financial news for TSRO dated on 2017-05-23: The Current State Of The Breast Cancer Treatment Space

Financial news for TSRO dated on 2017-05-11: TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer

Financial news for TSRO dated on 2017-05-09: TESARO Reports Q1 EPS \$(2.55) vs \$(2.24), Sales \$2.1M vs \$3.8M Est.

Financial news for TSRO dated on 2017-05-01: TESARO Reports Submission of INDA for TSR-033

Financial news for TSRO dated on 2017-04-28: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for TSRO dated on 2017-04-27: Benzinga's Option Alert Recap From April 27

Financial news for TSRO dated on 2017-04-27: Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space

Financial news for TSRO dated on 2017-04-27: Option Alert: Tesaro Jun 140 Calls: 711 @ ASK \$15.60: 1005 traded vs 116 OI: Earnings 5/9 After Close \$144.84 Ref

Financial news for TSRO dated on 2017-04-27: TESARO Reports Initiation of Registrational Development Program for Anti-PD-1 Antibody TSR-042

Financial news for TSRO dated on 2017-04-26: TESARO Reports Approval of VARUBY by EC

Financial news for TSRO dated on 2017-04-20: SunTrust Says Abbvie Failure Has No Negative Read Through For TESARO, Keeps Buy Rating And \$235 PT

Financial news for TSRO dated on 2017-04-19: Diplomat Pharmacy Announces Will Dispense ZEJULA

Financial news for TSRO dated on 2017-04-19: TESARO Reports Availability of Zejula for Patients with Recurrent Ovarian Cancer in US, Price is \$9,833/Month

Financial news for TSRO dated on 2017-04-18: Strength In TESARO Being Attributed By Traders To Vague Takeover Chatter

Financial news for TSRO dated on 2017-04-12: PiperJaffray Initiates Coverage On Tesaro at Overweight, Announces \$180.00 Price Target

Financial news for TSRO dated on 2017-04-07: TESARO Reports Winning of Awards for Clinical Development Team of the Year

Financial news for TSRO dated on 2017-04-05: Feuerstein Throws BioMarin Into Gilead Takeover Speculation

Financial news for TSRO dated on 2017-04-05: Feuerstein on Possibilities of Gilead Takeover Interest: Notes A Lot of Sources Have Talked About TESARO as Target, But Feels BioMarin is a Co. Which Has Better Chance to Move the Needle at Gilead

Financial news for TSRO dated on 2017-03-28: Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April

Financial news for TSRO dated on 2017-03-28: 7 Biggest Price Target Changes For Tuesday

Financial news for TSRO dated on 2017-03-28: How The Market For Tesaro's Niraparib Plays Out Following Early FDA Approval

Financial news for TSRO dated on 2017-03-28: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TSRO dated on 2017-03-28: Wedbush Reiterates Outperform On Tesaro, Raises Price Target To \$174

Financial news for TSRO dated on 2017-03-27: Tesaro Shares Now Up 5.53%; Co. Earlier Filed Form CT Requesting Confidential Treatment For Info Excluded From 10-Q Filed In November 2016

Financial news for TSRO dated on 2017-03-27: TESARO Shares Now Up 5.9% After Hours At \$166/Share

Financial news for TSRO dated on 2017-03-27: Tesaro Announces Expanded Development Program For Cancer Drug Niraparib, Stock Spikes Higher

Financial news for TSRO dated on 2017-03-27: TESARO Shares To Resume Trade At 4:20pm ET

Financial news for TSRO dated on 2017-03-27: Adam Feuerstein Tweets: \$TSRO -- I'd say this Zejula approval is best case for the company. They got everything they wanted from FDA in that label.

Financial news for TSRO dated on 2017-03-27: UPDATE: TESARO Says BRAVO Trial No Longer Expected To Serve As Registration Study, Says Investor Conf. Call And Webcast To Be Held At 4:30pm ET Today

Financial news for TSRO dated on 2017-03-27: TESARO PR Announces Expanded Development Program for Niraparib

Financial news for TSRO dated on 2017-03-27: Adam Feuerstein Tweets: Looks like FDA gave \$TSRO Zejula a broad label for ovarian cancer maintenance. BRCA mutation and non.

Financial news for TSRO dated on 2017-03-27: TESARO Shares Halted, FDA Site Shows FDA Approval For niraparib

Financial news for TSRO dated on 2017-03-27: Adam Feuerstein Tweets: And so many of you were hoping \$TSRO news would be a takeout....

Financial news for TSRO dated on 2017-03-27: TESARO Halted News Pending

Financial news for TSRO dated on 2017-03-24: Here Are The 4 Commercial Launches In 2017 That Earned Tesaro A Buy Rating At Argus

Financial news for TSRO dated on 2017-03-24: Argus Initiates Coverage On Tesaro With Buy, Announces \$210 Price Target

Financial news for TSRO dated on 2017-03-24: Watch These 10 Huge Call Purchases In Friday Trade

Financial news for TSRO dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for TSRO dated on 2017-03-15: 8 Biggest Price Target Changes For Wednesday

Financial news for TSRO dated on 2017-03-15: Lynparza Vs. Niraparib

Financial news for TSRO dated on 2017-03-15: Wedbush Cuts TESARO Target By 18% Following SOLO-2 Results

Financial news for TSRO dated on 2017-03-15: Wedbush Reiterates Outperform On Tesaro, Lowers Price Target To \$164

Financial news for TSRO dated on 2017-03-14: Adam Feuerstein Tweets: \$AZN Takes PARP Inhibitor Fight to Rival \$TSRO with Strong Ovarian Cancer Study Results --> thetstreet.com/story/14043007... \$CLVS, too.

Financial news for TSRO dated on 2017-03-14: Adam Feuerstein Tweet \$AZN Lynparza SOLO-2 ovarian cancer maintenance therapy data in 10 minutes. Watch \$TSRO \$CLVS for reaction, as well. Battle of the PARPs.

Financial news for TSRO dated on 2017-03-13: UPDATE: TESARO Announced ENGOT-OV16/NOVA Trial Showed Positive, Durable Treatment Effect of Niraparib in Patients with Ovarian

Cancer

Financial news for TSRO dated on 2017-03-13: TESARO Shares Make Parabolic Move, Spike to Session High Near \$176, Now Lower for Session as Traders Respond to Press Release Highlighting Presentation of Niraparib Phase 3 Results at SGO

Financial news for TSRO dated on 2017-03-13: Wall Street's M&A Chatter From March 10-12

Financial news for TSRO dated on 2017-02-28: TESARO Reports Q4 EPS \$(2.60) vs. \$(1.95) Est.

Financial news for TSRO dated on 2017-02-27: 8 Biggest Price Target Changes For Monday

Financial news for TSRO dated on 2017-02-27: Benzinga's Top Upgrades, Downgrades For February 27, 2017

Financial news for TSRO dated on 2017-02-27: Baird Downgrades Tesaro to Neutral, Raises price target to \$182.00

Financial news for TSRO dated on 2017-02-27: TESARO Receives Positive CHMP Opinion for VARUBY

Financial news for TSRO dated on 2017-02-24: EU Medicines Agency Recommends Approval of Tesaro's Rolapitant Against Chemo-Induced Nausea And Vomiting

Financial news for TSRO dated on 2017-02-22: venBio Says It's Committed TO Delivering Much-Needed Change At Immunomedics In Shareholder Letter

Financial news for TSRO dated on 2017-02-22: RBC Capital Markets Healthcare Conference Begins Today, Day 1 Of 2; Presenters Include Tesaro, Axovant, Gilead, And Puma Biotechnology

Financial news for TSRO dated on 2017-02-16: 7 Biggest Price Target Changes For Thursday

Financial news for TSRO dated on 2017-02-16: FBR Capital Downgrades Tesaro To Market Perform, Raises Price Target To \$202

Financial news for TSRO dated on 2017-02-16: Leerink Partners Global Healthcare Conference Concludes Today; Presenters Include Aurinia Pharmaceuticals, Karyopharm Therapeutics, Selecta Biosciences, TESARO, EXACT Sciences, Axovant Sciences, Achaogen

Financial news for TSRO dated on 2017-02-13: Key Presenters At Leerink's Healthcare Conference

Financial news for TSRO dated on 2017-02-10: venBio Comments on Immunomedics Partnership Announcement, Says Co. Blatantly Spurning Will Of Stockholders

Financial news for TSRO dated on 2017-02-10: Leerink Swann Downgrades Tesaro To Market Perform

Financial news for TSRO dated on 2017-02-09: The Market In 5 Minutes: Twitter Tanks, Trump Tweets, Tesla Preps

Financial news for TSRO dated on 2017-02-09: Wall Street's M&A Chatter From February 8

Financial news for TSRO dated on 2017-02-08: Hearing SunTrust Out WITH Comments Saying TESARO Could Be Worth \$250/Share

Financial news for TSRO dated on 2017-02-08: Tesaro Shares Resume Trading, Now Up 12+%

Financial news for TSRO dated on 2017-02-08: TESARO Shares Halted Up 10.9%

Financial news for TSRO dated on 2017-02-08: Tesaro Halted on CB; To Resume 11:36:54

Financial news for TSRO dated on 2017-02-08: Tesaro Discussing Options with Investments Banks Including Citigroup. Received Takeover Interest

Financial news for TSRO dated on 2017-02-08: TESARO Discussing Options With Investment Banks Following Acquisition Approaches

Financial news for TSRO dated on 2017-02-07: Franklin Resources Reports 5.7% Stake In TESARO

Financial news for TSRO dated on 2017-02-06: Benzinga's Top Upgrades, Downgrades For

February 6, 2017

Financial news for TSRO dated on 2017-02-06: Cowen & Co. Initiates Coverage On Tesaro At Market Perform

Financial news for TSRO dated on 2017-01-27: The Market In 5 Minutes: Google And Microsoft And Intel, Oh My!

Financial news for TSRO dated on 2017-01-27: Wall Street's M&A Chatter From January 26

Financial news for TSRO dated on 2017-01-26: Recent Strength In Tesoro Being Attributed To Takeover Chatter

Financial news for TSRO dated on 2017-01-17: Tesaro Expands Scope of Access to Niraparib for U.S. Patients With Ovarian Cancer

Financial news for TSRO dated on 2017-01-13: TESARO Shares Up 6% as Morgan Stanley Earlier Initiated Coverage with Overweight Rating

Financial news for TSRO dated on 2017-01-12: Tesaro Shares Lower On Receipt Of FDA Complete Response Letter

Financial news for TSRO dated on 2017-01-12: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for TSRO dated on 2017-01-12: TESARO Receives CRL from FDA for Rolapitant IV Requesting Additional Information

Financial news for TSRO dated on 2017-01-11: Tesaro PDUFA Date For Rolapitant - Intravenous Is Today

Financial news for TSRO dated on 2017-01-05: Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

Financial news for TSRO dated on 2017-01-05: Incyte, TESARO, BioMarin Shares Lower, Neurocrine Bio Shares Higher; Hearing Jefferies Classified Cos. as 'Most Favored M&A Targets'

Financial news for TSRO dated on 2016-12-28: A Preview Of January PDUFA Dates

Financial news for TSRO dated on 2016-12-27: 5 Biggest Price Target Changes For Tuesday

Financial news for TSRO dated on 2016-12-23: 15 Stocks With The Highest Forecast Sales Growth

Financial news for TSRO dated on 2016-12-23: 6 Best Biotech Stocks Of 2016

Financial news for TSRO dated on 2016-12-21: Breaking Down The Crowded Novel Ovarian Cancer Treatment Space

Financial news for TSRO dated on 2016-12-20: Clovis' Rubraca Vs. TESARO's Niraparib

Financial news for TSRO dated on 2016-12-20: Tesaro Announces Priority Review Designation for Niraparib NDA, NDA Accepted For FDA Review With PDUFA Date Of June 30, 2017

Financial news for TSRO dated on 2016-12-19: Adam Feuerstein Tweets '\$CLVS Rubraca approval has little bearing on \$TSRO given different ovarian cancer pat pops. Rubraca more competes w/ \$AZN Lynparza.'

Financial news for TSRO dated on 2016-12-19: FDA Approves Clovis Oncology's Ovarian Cancer Treatment

Financial news for TSRO dated on 2016-12-19: TESARO Shares Spike ~\$3 Lower Following News Out on Clovis' Rubraca

Financial news for TSRO dated on 2016-11-15: 15 Biggest Mid-Day Losers For Tuesday

Financial news for TSRO dated on 2016-11-15: The Technical Take: Street Scorns Tesaro's \$135/Share Offering Price

Financial news for TSRO dated on 2016-11-15: Tesoro Offering Of 1.75M Shares Priced At \$135/Share

Financial news for TSRO dated on 2016-11-15: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TSRO dated on 2016-11-15: Adam Feuerstein @adamfeuerstein Tweet: \$TSRO - I'm hearing investor demand light for stock offering announced last night. Pricing closer to \$135 than \$140, speculates my source.

Financial news for TSRO dated on 2016-11-14: TESARO Announces Proposed Public Offering of 1.75M Shares Of Common Stock

Financial news for TSRO dated on 2016-11-06: Barron's: Stock Pickers Are Leading The Charge

Financial news for TSRO dated on 2016-11-04: Raymond James Downgrades TESARO, Inc. - Common Stock to Market Perform

Financial news for TSRO dated on 2016-11-03: TESARO Reports Q3 EPS \$(1.98) vs. Est. \$(1.92)

Financial news for TSRO dated on 2016-11-01: Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer

Financial news for TSRO dated on 2016-10-27: TESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMA

Financial news for TSRO dated on 2016-10-24: TESARO Shares Spike Over \$117.50 as Hearing Takeover Chatter

Financial news for TSRO dated on 2016-10-11: Bloomberg Reporter Caroline Chen Tweets: Federal judge on Oct. 7 refused \$TSRO request for restraining order on \$MYGN press release on NOVA -- via @business

Financial news for TSRO dated on 2016-10-10: Mid-Afternoon Market Update: Gas Natural Jumps After Merger News; Twilio Shares Drop

Financial news for TSRO dated on 2016-10-10: The ESMO Conference Proves Its Ability To Move Stocks

Financial news for TSRO dated on 2016-10-10: Technical Alert: TESARO Inc. Soars To New All-Time-High After Positive Trial Data And Upgrades

Financial news for TSRO dated on 2016-10-10: TESARO Shares Pull Back ~2.6% from Session Highs Following Adam F. Article on TheStreet

Financial news for TSRO dated on 2016-10-10: Adam Feuerstein @adamfeuerstein Even High-Flying \$TSRO and its Ovarian Cancer Drug has a Bear Thesis. Here it is, Explained thestreet.com/story/13847520... via @TheStreet

Financial news for TSRO dated on 2016-10-10: What TESARO's Phase 3 NOVA Results Mean For Myriad Genetics

Financial news for TSRO dated on 2016-10-10: 12 Biggest Mid-Day Gainers For Monday

Financial news for TSRO dated on 2016-10-10: Mid-Day Market Update: Crude Oil Up 3%; Twitter Shares Slide

Financial news for TSRO dated on 2016-10-10: Credit Suisse Hikes TESARO Target Price to \$122 On Robust Niraparib Data; Shares Up

Financial news for TSRO dated on 2016-10-10: Citi Sees 26% Upside In TESARO On The Strength Of Trial Data

Financial news for TSRO dated on 2016-10-10: Benzinga's Volume Movers

Financial news for TSRO dated on 2016-10-10: Mid-Morning Market Update: Markets Open Higher; Dover Lowers Full-Year Forecast

Financial news for TSRO dated on 2016-10-10: 5 Biggest Price Target Changes For Monday

Financial news for TSRO dated on 2016-10-10: Benzinga's Top Upgrades

Financial news for TSRO dated on 2016-10-10: Wedbush Raises TESARO Price Target From \$107 To \$139

Financial news for TSRO dated on 2016-10-10: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for TSRO dated on 2016-10-10: Bank of America Upgrades TESARO, Inc. to Buy

Financial news for TSRO dated on 2016-10-09: Myriad Genetics Announces myChoice HRD

Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib

Financial news for TSRO dated on 2016-10-09: TESARO, ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016

Financial news for TSRO dated on 2016-10-07: Celldex, Endocyte And Tesaro Expected To Present Data At European Society For Medical Oncology Conf.

Financial news for TSRO dated on 2016-10-03: Watch These Huge Put Purchases In Monday Trade

Financial news for TSRO dated on 2016-09-30: Option Alert: TSRO Oct16 95.0 Puts Sweep: 500 @ ASK \$5.20: 503 traded vs 294 OI: Earnings 11/3 \$99.75 Ref

Financial news for TSRO dated on 2016-09-29: TESARO and Zai Lab to Collaborate for the Commercialization of Niraparib in China

Financial news for TSRO dated on 2016-09-22: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for TSRO dated on 2016-09-21: Option Alert: TSRO Fri \$115 Calls at the ask: Volume of 1,500 @ 6.201 vs 1 Open Interest

Financial news for TSRO dated on 2016-09-20: 18 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for TSRO dated on 2016-09-16: TESARO Shares Trading Up ~2% in Otherwise Down Tape on No News; Some Traders Getting Anxious Following News of Gilead \$5B Senior Notes Offering Announced Thurs. Evening

Financial news for TSRO dated on 2016-09-13: Recent Strength In TESARO Being Attributed To Gabelli Research Report Of Potential Gilead Interest In TESARO

Financial news for TSRO dated on 2016-09-12: TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission

Financial news for TSRO dated on 2016-09-12: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for TSRO dated on 2016-09-09: Tesaro Oct \$120 Calls at the bid: 1000 @ 1.75 vs. Open Interest 9

Financial news for TSRO dated on 2016-09-08: Option Alert: TSRO Sep16 80.0 Calls: 1000 @ ASK \$15.30: 1015 traded vs 1243 OI: \$94.80 Ref

Financial news for TSRO dated on 2016-09-08: TESARO Shares Now Up 6%

Financial news for TSRO dated on 2016-09-08: Traders Attributing Strength in TESARO Shares to Comment from Gilead Exec Mgmt is 'Absolutely Willing' to Take Risk with Right PARP Product

Financial news for TSRO dated on 2016-09-08: Tesaro Spikes to High of \$93.95 on Volume

Financial news for TSRO dated on 2016-09-06: Lake Street Says Buy-Rated Tesaro Holds An Attractive Portfolio Of Cancer Therapies

Financial news for TSRO dated on 2016-09-06: Lake Street Assumes Tesaro at Buy, Announces \$114.00 PT

Financial news for TSRO dated on 2016-08-30: Benzinga's Top Initiations

Financial news for TSRO dated on 2016-08-30: Bank of America Initiates Coverage on Tesaro at Neutral

Financial news for TSRO dated on 2016-08-23: Adam Feuerstein @adamfeuerstein Tweet: \$TSRO down today on Favus bear note. 12:31pm * 23 Aug 201

Financial news for TSRO dated on 2016-08-22: Tesaro +3.13% Premarket @\$98.00; Moving in Sympathy with Medivation Following Acquisition Announcement

Financial news for TSRO dated on 2016-08-12: Benzinga's Top Initiations

Financial news for TSRO dated on 2016-08-12: RBC Capital Initiates Coverage on Tesaro at Outperform

Financial news for TSRO dated on 2016-08-04: Tesaro Reports Q2 EPS \$(1.28) vs. Est. \$(1.71)

Financial news for TSRO dated on 2016-07-19: Benzinga's Top Initiations

Financial news for TSRO dated on 2016-07-19: The Market In 5 Minutes: Netflix Earnings Disappoint, Goldman Sachs Has Big Beat

Financial news for TSRO dated on 2016-07-19: Baird Initiates Coverage on Tesaro at Outperform

Financial news for TSRO dated on 2016-07-18: Baird Initiates Tesaro Shares with Outperform Rating, \$105 Price Target

Financial news for TSRO dated on 2016-07-08: ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial, Achieves Primary Endpoint In BRCA Mutant Cohort And Non-Germline Cohort

Financial news for TSRO dated on 2016-07-08: Tesaro Sells off to Low of \$87.91

Financial news for TSRO dated on 2016-07-01: Citi Raises TESARO Price Target 38%, Sees 16.3% Upside

Financial news for TSRO dated on 2016-07-01: 9 Biggest Mid-Day Losers For Friday

Financial news for TSRO dated on 2016-07-01: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for TSRO dated on 2016-07-01: TESARO Prices 4.65M Share Offering @\$81.00/Share

Financial news for TSRO dated on 2016-06-30: TESARO Commences Public Offering Worth \$300 Million

Financial news for TSRO dated on 2016-06-30: Jefferies Downgrades Tesaro Following 108% Stock Move

Financial news for TSRO dated on 2016-06-30: Jefferies Downgrades Tesaro to Hold

Financial news for TSRO dated on 2016-06-30: Benzinga's Top Downgrades

Financial news for TSRO dated on 2016-06-30: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for TSRO dated on 2016-06-30: Tesaro Shares Fall Sharply to Low of \$72.51 Following Announcement of \$300M Offering

Financial news for TSRO dated on 2016-06-30: Tesaro Announces \$300M Common Stock Offering

Financial news for TSRO dated on 2016-06-30: Tesaro Files for Mixed Shelf; Amount Not Disclosed

Financial news for TSRO dated on 2016-06-29: Mid-Afternoon Market Update: Dow Jumps Over 250 Points; Diamond Resorts Shares Climb Following Apollo Deal

Financial news for TSRO dated on 2016-06-29: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for TSRO dated on 2016-06-29: Mid-Day Market Update: Crude Oil Surges 3%; Galena Biopharma Shares Tumble

Financial news for TSRO dated on 2016-06-29: Tesaro Doubles Off Ovarian Cancer Drug Trial Results

Financial news for TSRO dated on 2016-06-29: Benzinga's Volume Movers

Financial news for TSRO dated on 2016-06-29: TESARO Spikes 110% After Drug Significantly Improved Progression-Free Survival For Ovarian Cancer Patients

Financial news for TSRO dated on 2016-06-29: Stocks Hitting 52-Week Highs

Financial news for TSRO dated on 2016-06-29: Mid-Morning Market Update: Markets Open Higher; General Mills Profit Tops Expectations

Financial news for TSRO dated on 2016-06-29: Clovis Oncology Up 19.38% At \$14.70/Share In Sympathy To Tesaro

Financial news for TSRO dated on 2016-06-29: 13 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TSRO dated on 2016-06-29: Myriad Genetics Reports myChoice HRD

Test Successfully Identified Patients Who Met Primary Endpoint in TESARO's Study with Niraparib

Financial news for TSRO dated on 2016-06-29: TESARO Reports Niraparib Significantly Improved Progression-Free Survival for Patients with Ovarian Cancer

Financial news for TSRO dated on 2016-06-04: TESARO Announces FDA has Accepted for Review the NDA for IV Formulation of Rolapitant at #ASCO16

Financial news for TSRO dated on 2016-05-13: Benzinga's Top Initiations

Financial news for TSRO dated on 2016-05-13: Credit Suisse Initiates Coverage on Tesaro at Outperform, Announces \$56.00 PT

Financial news for TSRO dated on 2016-05-10: Steven Cohen Reports 5.3% Passive Stake in Tesaro in 13G

Financial news for TSRO dated on 2016-05-05: Tesaro Reports Q1 EPS \$(2.22) Vs Est \$(1.69)

Financial news for TSRO dated on 2016-04-13: FBR Capital Initiates Coverage on Tesaro at Outperform

Financial news for TSRO dated on 2016-04-08: Friday's After-Hours Movers: Energy, Pharmaceuticals Active

Financial news for TSRO dated on 2016-04-06: TESARO Reports Global Prostate Cancer Partnership and Licensing Agreement With Janssen, TESARO To Receive \$450M in Upfront & Milestone Payments With Royalties

Financial news for TSRO dated on 2016-03-29: TESARO, MD Anderson Cancer Center Report Immuno-Oncology Partnership & Exclusive License Agreement

Financial news for TSRO dated on 2016-03-29: TESARO Enrolls First Patient In Phase 1 Trial Of TSR-042

Financial news for TSRO dated on 2016-03-23: TESARO Reports Validation of MAA for Oral Rolapitant by EMA

Financial news for TSRO dated on 2016-03-17: Benzinga's Top Initiations

Financial news for TSRO dated on 2016-03-17: Citigroup Initiates Coverage on Tesaro at Buy, Announces \$65.00 PT

Financial news for TSRO dated on 2016-03-14: TESARO Submits NDA To FDA For Intravenous Rolapitant

Financial news for TSRO dated on 2016-02-25: UPDATE: Tesaro Says US Commercial Launch Of VARUBI Is Well Underway , Plans To Submit NDA For Niraparib In H2 2016

Financial news for TSRO dated on 2016-02-25: TESARO Reports Q4 EPS \$(1.89) vs \$(1.63) Est.

Financial news for TSRO dated on 2016-02-22: Myriad Genetics Announces Expansion of Collaboration with Merck and Tesaro

Financial news for TSRO dated on 2016-02-05: Benzinga's Top Initiations

Financial news for TSRO dated on 2016-02-05: Lake Street Initiates Coverage on Tesaro at Buy

Financial news for TSRO dated on 2016-01-20: Wedbush Initiates Coverage on Tesaro at Outperform, Announces \$72.00 PT

Financial news for TSRO dated on 2016-01-11: Tesaro Shares Spiking Higher

Financial news for TSRO dated on 2016-01-11: TESARO Reports Strategic Outlook For 2016, niraparib NOVA and QUADRA Registration Trials Expected Q2 2016

Financial news for TSRO dated on 2015-12-04: Wells Fargo Initiates Coverage on Tesaro at Outperform

Financial news for TSRO dated on 2015-11-16: UPDATE: OPKO, TESARO Release Shows 'More than half of patients undergoing emetogenic chemotherapy may experience delayed CINV, even when prescribed a 5-HT3 receptor antagonist and a corticosteroid'

Financial news for TSRO dated on 2015-10-29: TESARO Reports Q3 EPS (1.66) vs. Est. \$(1.52)

Financial news for TSRO dated on 2015-10-20: Vaccinex Announces Publication of Results From a Phase I Trial of Anti-Semaphorin 4D Antibody, VX15/2503, in Patients With Advanced Solid Tumors

Financial news for TSRO dated on 2015-09-24: TESARO Announces Inclusion of VARUBI in NCCN Antiemesis Guidelines

Financial news for TSRO dated on 2015-09-21: Tesaro Appoints Martin Huber, M.D., as SVP and Chief Medical Officer

Financial news for TSRO dated on 2015-09-08: A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month

Financial news for TSRO dated on 2015-09-02: TESARO Announces U.S. FDA Approval of VARUBI for Nausea and Vomiting Associated With Cancer Chemotherapy

Financial news for TSRO dated on 2015-08-20: 10 Biotech Stocks With Catalysts Coming Soon

Financial news for TSRO dated on 2015-08-13: This Week's First IPO: Global Blood Therapeutics Developing Drugs For Diseases Affecting Few

Financial news for TSRO dated on 2015-08-06: TESARO Reports Q2 EPS \$(1.51) vs. Est. \$(1.14)

Financial news for TSRO dated on 2015-07-30: Tesaro, Jiangsu Hengrui Medicine Report Rolapitant License Agreement For China

Financial news for TSRO dated on 2015-07-13: TESARO Names Grant Bogle Chief Commercial Officer

Financial news for TSRO dated on 2015-06-29: TESARO Names Jeffrey Hank, Ph.D, EVP & Chief Scientific Officer

Financial news for TSRO dated on 2015-05-30: TESARO, Merck to Collaborate on Combination Study of Niraparib, KEYTRUDA

Financial news for TSRO dated on 2015-05-30: TESARO Announces Successful Completion of Rolapitant Bioequivalence Study

Financial news for TSRO dated on 2015-04-30: Tesaro Reports Q1 EPS -\$1.30 Vs Est -\$1.12

Financial news for TSRO dated on 2015-03-09: TESARO Closes Stock Offering, Net Proceeds Are Approx. \$179.7M

Financial news for TSRO dated on 2015-03-04: Morning Market Losers

Financial news for TSRO dated on 2015-03-04: Benzinga's Top #PreMarket Losers

Financial news for TSRO dated on 2015-03-04: TESARO Prices 3.4M Share Offering at \$51.00/Share

Financial news for TSRO dated on 2015-03-02: TESARO Announces \$150M Common Stock Offering

Financial news for TSRO dated on 2015-02-23: Citigroup Adds Tesaro To 'Focus List,' Removes Medivation

Financial news for TSRO dated on 2015-01-30: Stocks That Battle Cancer Were The Best-Performing Biotechs In January

Financial news for TSRO dated on 2015-01-12: TESARO Announces Expansion of Niraparib Clinical Program, Provides 2015 Update

Financial news for TSRO dated on 2014-12-02: TESARO, AnaptysBio Expand Immuno-Oncology Collaboration

Financial news for TSRO dated on 2014-11-20: TESARO and Myriad Genetics Form Collaboration Utilizing Myriad's myChoice HRD Companion Diagnostic

Financial news for TSRO dated on 2014-10-07: Benzinga's Top Initiations

Financial news for TSRO dated on 2014-10-07: Jefferies Initiates TESARO At Buy

Financial news for TSRO dated on 2014-10-07: Jefferies Initiates Coverage on TESARO, Inc. at Buy, Announces \$40.00 PT

Financial news for TSRO dated on 2014-10-02: Guggenheim Securities Initiates Coverage

on TESARO, Inc. at Buy, Announces \$46.00 PT

Financial news for TSRO dated on 2014-09-22: TESARO Announces Offering of \$165 Million of Convertible Senior Notes Due 2021

Financial news for TSRO dated on 2014-09-22: TRACON Pharmaceuticals Completes \$27M Financing And Expands Management Team And Board of Directors

Financial news for TSRO dated on 2014-09-08: OPKO Reports Licensee TESARO Has Submitted NDA for Rolapitant, Will Get Payments of Up to \$121M

Financial news for TSRO dated on 2014-09-08: TESARO Announces Submission Of Rolapitant New Drug Application To FDA

Financial news for TSRO dated on 2014-06-01: Tesaro Summarizes Phase 3 Rolapitant Data Presented at ASCO 2014

Financial news for TSRO dated on 2014-05-27: TESARO Announces Tim Pearson CFO

Financial news for TSRO dated on 2014-05-27: Actinium Set To Follow In Opko's Foosteps Amid Near Term Catalysts

Financial news for TSRO dated on 2014-05-12: Market Wrap For May 12: Dow And S&P Close At Record Highs

Financial news for TSRO dated on 2014-05-12: Mid-Afternoon Market Update: Markets Rally As INSYS Therapeutics Drops On Fraud Headline

Financial news for TSRO dated on 2014-05-12: Mid-Day Market Update: Gogo Surges On Upbeat Results; Core Laboratories Shares Slide

Financial news for TSRO dated on 2014-05-12: Mid-Morning Market Update: Markets Rally; Hillshire Brands To Acquire Pinnacle Foods For \$6.6B

Financial news for TSRO dated on 2014-05-12: Benzinga's Volume Movers

Financial news for TSRO dated on 2014-05-12: Morning Market Movers

Financial news for TSRO dated on 2014-05-12: Benzinga's Top #PreMarket Gainers

Financial news for TSRO dated on 2014-05-12: UPDATE: Tesaro Shares Rise 13% Premarket Following Announcement of Successful Primary and Secondary Endpoints in Final Phase 3 Trial For Rolapitant

Financial news for TSRO dated on 2014-05-12: Tesaro Announces Statistical Significant For Primary and Secondary Endpoints For NK-1

Financial news for TSRO dated on 2014-05-12: Tesaro Announces Successful Primary and Secondary Endpoints in Final Phase 3 Trial For Rolapitant

Financial news for TSRO dated on 2014-04-30: TESARO, Inc. Reports Q1 EPS of \$(1.43) vs \$(1.06) Est

Financial news for TSRO dated on 2014-03-24: Myriad Announces HRD Companion Diagnostic Collaboration With Tesaro

Financial news for TSRO dated on 2014-03-13: Market Wrap For March 13: Bears Come Out Of Hibernation As Dow Suffers Largest Daily Loss Since February 3

Financial news for TSRO dated on 2014-03-13: Tesaro Spikes to High Following Positive Deutsche Bank Comments

Financial news for TSRO dated on 2014-02-19: TESARO, Inc. Reports Q4 EPS of \$(0.72) vs \$(0.81) Est

Financial news for TSRO dated on 2014-02-04: UPDATE: Morgan Stanley Downgrades TESARO from Overweight to Equalweight, PT Lowered to \$30

Financial news for TSRO dated on 2014-02-04: Benzinga's Top Downgrades

Financial news for TSRO dated on 2014-02-04: Morgan Stanley Downgrades TESARO, Inc. to Equal-weight, Lowers PT to \$30.00

Financial news for TSRO dated on 2014-01-28: TESARO Announces \$100M Proposed Public Offering of Common Stock

Financial news for TSRO dated on 2014-01-23: Tesaro Spikes Lower; May be Attributed to Removal from Short-Term Buy List at Deutsche Bank

Financial news for TSRO dated on 2014-01-21: Market Wrap For January 21: Dow Hit by Earnings; S&P And Nasdaq End The Day Positive

Financial news for TSRO dated on 2014-01-21: UPDATE: BMO Capital Markets Upgrades Tesaro

Financial news for TSRO dated on 2014-01-21: BMO Capital Upgrades TESARO, Inc. to Outperform, Raises PT to \$46.00

Financial news for TSRO dated on 2013-12-23: Tesaro Shares Tumble After Disappointing Data Results

Financial news for TSRO dated on 2013-12-23: Mid-Morning Market Update: Markets Surge; Seagate To Acquire Xyratex For \$374M

Financial news for TSRO dated on 2013-12-23: Morning Market Losers

Financial news for TSRO dated on 2013-12-23: TESARO's Rolapitant Achieve Primary Endpoint in Each of Two Phase 3 Trials for Prevention of CINV

Financial news for TSRO dated on 2013-11-07: TESARO, Inc. Reports Q3 EPS of \$(0.88) vs \$(0.69) Est

Financial news for TSRO dated on 2013-09-29: TESARO Presents Initial Phase 1 Clinical Data for TSR-011 at ECC 2013

Financial news for TSRO dated on 2013-08-06: Market Wrap for Tuesday, August 6: Possibility Of September Fed Taper Weighs On Risk Assets

Financial news for TSRO dated on 2013-07-29: Market Wrap for Monday, July 29: Stocks Record Moderate Losses to Start Trading Week

Financial news for TSRO dated on 2013-07-25: TESARO, Inc. Reports Q2 EPS of \$(0.67) vs \$(0.27) Est

Financial news for TSRO dated on 2013-07-23: TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer

Financial news for TSRO dated on 2013-07-09: Market Wrap for Tuesday, July 9: Major Averages Closing in on Previous Highs

Financial news for TSRO dated on 2013-06-25: Mizuho Securities Initiates Coverage on TESARO, Inc. at Buy, Announces \$44.00 PT

Financial news for TSRO dated on 2013-06-24: Myriad and TESARO Enter Into Companion Diagnostic Agreement

Financial news for TSRO dated on 2013-06-19: UPDATE: BMO Capital Markets Downgrades Tesaro on Limited Upside Potential

Financial news for TSRO dated on 2013-06-19: BMO Capital Downgrades TESARO, Inc. to Market Perform, Maintains \$36.00 undefined

Financial news for TSRO dated on 2013-06-05: Market Wrap for Wednesday, June 5: Stocks Plunge as Uncertainty Rises

Financial news for TSRO dated on 2013-06-05: Afternoon Market Losers

Financial news for TSRO dated on 2013-06-04: UPDATE: TESARO Issues Details on Niraparib Phase 1 Clinical Data, Recist Response Rate 75% Achieved at 300mg Dose, 50% Achieved Across All Dose Levels

Financial news for TSRO dated on 2013-06-04: TESARO Issues Details on Niraparib Phase 1 Clinical Data, Recist Response Rate 75% Achieved at 300mg Dose, 50% Achieved Across All Dose Levels

Financial news for TSRO dated on 2013-06-03: Market Wrap for Monday, June 3: Stocks Rise to Start Week

Financial news for TSRO dated on 2013-06-03: TESARO Target Boosted Sharply from \$45 to \$85 at Deutsche Bank

Financial news for TSRO dated on 2013-06-03: BioMarin Shares Remain at Lows Despite Piper Jaffray Note Defending News of Clovis, Tesaro Data Updates at ASCO, Says BioMarin's BMN-673 'Looks Competitive;' Reiterates Overweight, \$70 Target

Financial news for TSRO dated on 2013-06-03: TESARO, ENGOT Announce Partnership to Develop Niraparib for Ovarian Cancer

Financial news for TSRO dated on 2013-06-03: TESARO, Breast International Group, European Organization for Research and Treatment of Cancer Announce Collaboration

Financial news for TSRO dated on 2013-05-16: Market Wrap for Thursday, May 16: A Small Pullback For U.S. Stocks as Economic Data Disappoints

Financial news for TSRO dated on 2013-05-16: Tesaro Final Phase 1 Results Demonstrate Activity in Ovarian and Breast Cancer, Phase 3 Trial for Ovarian Cancer to Begin Mid-Year

Financial news for TSRO dated on 2013-05-15: Stocks Hitting 52-Week Highs

Financial news for TSRO dated on 2013-04-29: Stocks Hitting 52-Week Highs

Financial news for TSRO dated on 2013-04-25: TESARO, Inc. Reports Q1 EPS of \$(0.66), Inline

Financial news for TSRO dated on 2013-04-11: Tesaro Moves Lower; May be Attributed to Negative Seeking Alpha Article

Financial news for TSRO dated on 2013-04-09: Benzinga's Volume Movers

Financial news for TSRO dated on 2013-03-27: Market Wrap for Wednesday, March 27: Stocks Close Mixed as Nasdaq Turns Positive

Financial news for TSRO dated on 2013-03-21: BMO Capital Maintains Outperform on TESARO, Inc., Raises PT to \$36.00

Financial news for TSRO dated on 2013-03-05: TESARO Close Offering, Full Exercise of Underwriter's Over-Allotment Option

Financial news for TSRO dated on 2013-02-28: A Peek Into The Market Before The Trading Starts

Financial news for TSRO dated on 2013-02-28: TESARO Prices 4.72M Share Offering at \$18.00/Share

Financial news for TSRO dated on 2013-02-20: TESARO, Inc Files Prospectus for Up to \$75M in Common Stock

Financial news for TSRO dated on 2013-02-14: TESARO, Inc. Reports Q4 EPS of \$(0.70) vs \$(0.65) Est

Financial news for TSRO dated on 2013-02-06: UPDATE: Deutsche Bank Initiates Coverage on Tesaro with Buy Rating, \$27 PT on Potential Upside

Financial news for TSRO dated on 2013-02-06: UPDATE: Deutsche Bank Initiates TESARO to Buy on Pipeline Upside

Financial news for TSRO dated on 2013-02-06: Benzinga's Top Initiations

Financial news for TSRO dated on 2013-02-06: Deutsche Bank Initiates Coverage on TESARO, Inc. at Buy, Announces \$27.00 PT

Financial news for TSRO dated on 2012-11-26: Stocks Hitting 52-Week Highs

Financial news for TSRO dated on 2012-10-25: Tesaro Reports Q3 EPS \$-0.52 vs \$-0.58 Est

Financial news for TSRO dated on 2012-07-24: BMO Capital Markets Initiates Coverage on Tesaro at Outperform, Announces PT of \$22

Financial news for TSRO dated on 2012-07-23: UPDATE: Morgan Stanley Initiates Coverage on Tesaro at Overweight

Financial news for TSRO dated on 2012-07-23: UPDATE: Morgan Stanley Initiates Tesaro at Overweight with \$19 PT on Low Risk to Lead Asset

Financial news for TSRO dated on 2012-07-23: Benzinga's Top Initiations

Financial news for TSRO dated on 2012-07-23: Leerink Swann Initiates Coverage on Tesaro at Outperform

Financial news for TSRO dated on 2012-07-23: Citigroup Initiates Coverage on Tesaro at Buy, Announces PT of \$21

Financial news for TSRO dated on 2012-07-23: Morgan Stanley Initiates Coverage on Tesaro at Overweight, Announces PT of \$19

Financial news for TSRO dated on 2012-06-28: From Earlier: TESARO Announces Pricing of 6M Share IPO at \$13.50